Suppr超能文献

定量评估在牛中使用恩诺沙星剂量方案时治疗效果和耐药性传播之间的权衡。

Quantifying trade-offs between therapeutic efficacy and resistance dissemination for enrofloxacin dose regimens in cattle.

机构信息

Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, 27695, USA.

Department of Mathematics, University of Tennessee, Knoxville, TN, USA.

出版信息

Sci Rep. 2024 Sep 4;14(1):20598. doi: 10.1038/s41598-024-70741-8.

Abstract

The use of antimicrobial drugs in food-producing animals contributes to the selection pressure on pathogenic and commensal bacteria to become resistant. This study aims to evaluate the existence of trade-offs between treatment effectiveness, cost, and the dynamics of resistance in gut commensal bacteria. We developed a within-host ordinary differential equation model to track the dynamics of antimicrobial drug concentrations and bacterial populations in the site of infection (lung) and the gut. The model was parameterized to represent enrofloxacin treatment for bovine respiratory disease (BRD) caused by Pastereulla multocida in cattle. Three approved enrofloxacin dosing regimens were compared for their effects on resistance on P. multocida and commensal E. coli: 12.5 mg/kg and 7.5 mg/kg as a single dose, and 5 mg/kg as three doses. Additionally, we explored non-FDA-approved regimes. Our results indicated that both 12.5 mg/kg and 7.5 mg/kg as a single dose scenario increased the most the treatment costs and prevalence of P. multocida resistance in the lungs, while 5 mg/kg as three doses increased resistance in commensal E. coli bacteria in the gut the most out of the approved scenarios. A proposed non-FDA-approved scenario (7.5 mg/kg, two doses 24 h apart) showed low economic costs, minimal P. multocida, and moderate effects on resistant E. coli. Overall, the scenarios that decrease P. multocida, including resistant P. multocida did not coincide with those that decrease resistant E. coli the most, suggesting a trade-off between both outcomes. The sensitivity analysis suggests that bacterial populations were the most sensitive to drug conversion factors into plasma ( ), elimination of the drug from the colon ( ), fifty percent sensitive bacteria (P. multocida) killing effect ( ), fifty percent of bacteria (E. coli) above ECOFF killing effect ( ), and net drug transfer rate in the lung ( ) parameters.

摘要

在食用动物中使用抗菌药物会导致致病菌和共生菌产生耐药性的选择压力。本研究旨在评估治疗效果、成本和肠道共生菌耐药性动态之间是否存在权衡。我们开发了一个体内常微分方程模型来跟踪抗菌药物浓度和感染部位(肺部)和肠道中细菌种群的动态。该模型被参数化,以代表恩诺沙星治疗多杀巴斯德氏菌引起的牛呼吸疾病(BRD)。比较了三种批准的恩诺沙星给药方案对多杀巴斯德氏菌和共生大肠杆菌耐药性的影响:12.5mg/kg 和 7.5mg/kg 作为单次剂量,5mg/kg 作为三次剂量。此外,我们还探讨了非 FDA 批准的方案。我们的研究结果表明,12.5mg/kg 和 7.5mg/kg 作为单次剂量的方案最能增加治疗成本和肺部多杀巴斯德氏菌耐药性的流行率,而 5mg/kg 作为三次剂量的方案最能增加肠道共生大肠杆菌耐药性。一个提议的非 FDA 批准方案(7.5mg/kg,两次剂量,间隔 24 小时)显示出较低的经济成本、最小的多杀巴斯德氏菌和对耐药大肠杆菌的适度影响。总体而言,降低多杀巴斯德氏菌的方案,包括耐药多杀巴斯德氏菌,与降低耐药大肠杆菌的方案并不一致,这表明这两种结果之间存在权衡。敏感性分析表明,细菌种群对药物向血浆的转化率( )、药物从结肠的消除率( )、对 50%敏感细菌(多杀巴斯德氏菌)的杀伤效应( )、对 50%以上细菌(大肠杆菌)的杀伤效应( )和肺部的净药物转移率( )参数最为敏感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a9e/11374901/62e32ad9a44d/41598_2024_70741_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验